ArticleCardiology and therapy2026
Prognostic Role of the PRECISE-DAPT Score in Acute Coronary Syndrome and Different Antithrombotic Treatment Strategies.
Article in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antithrombotic Therapy After PCI in High-Risk Cardiovascular Patients: Navigating Complexity Beyond Guidelines.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe PRECISE-DAPT score is a useful tool for predicting the risk of bleeding after percutaneous coronary intervention (PCI) requiring dual antiplatelet therapy. We aimed to validate the PRECISE-DAPT score as a mid-term mortality predictor in acute coronary syndrome (ACS).
methodsAll patients with ACS hospitalized between October 2018 and October 2023 were analyzed. Mortality data were acquired in cooperation with the Institute of Health Information and Statistics of the Czech Republic. We used a standard PRECISE-DAPT threshold ≥ 25. A receiver operating characteristic (ROC) curve analysis was used to assess the predictive performance of the PRECISE-DAPT score for mortality with a mean follow-up of 1.9 years. Area under the curve (AUC) was calculated for each ACS subtype and different antithrombotic strategy regimes at discharge to quantify discrimination ability, with higher values indicating better prediction.
resultsWe included 2953 patients with ACS. There were mostly men (69.1%, n = 2040), 37.1% ST-elevation myocardial infarction (STEMI, n = 1095), 45.2% non-ST-elevation myocardial infarction (NSTEMI, n = 1336) and 17.7% unstable angina pectoris (UAP, n = 522) patients. The mean age was 67.4 (SD 12.5) years. There were 78.4% patients treated by PCI (n = 2314). The PRECISE-DAPT score best predicts mortality in STEMI, AUC = 0.84 (95% confidence interval [CI] from 0.82 to 0.87), while its predictive ability is lower for NSTEMI, 0.78 (95% CI from 0.76 to 0.80) and UAP 0.75 (95% CI from 0.71 to 0.79). Antithrombotic treatment strategy at discharge does not influence the predictive ability of the PRECISE-DAPT score (AUC = 0.78, 071 and 0.72 for dual antiplatelet therapy, dual antithrombotic therapy, and triple therapy, respectively), p = 0.61.
conclusionsThe PRECISE-DAPT score may be used for predicting mid-term all-cause mortality in acute coronary syndrome, with the best predictive ability in STEMI. The standard threshold ≥ 25 maintain acceptable prognostic performance regardless of antithrombotic treatment strategy at discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.